Clinical Trials Directory

Trials / Completed

CompletedNCT00327834

Atomoxetine in the Treatment of Binge Eating Disorder

Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
Lindner Center of HOPE · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Conditions

Interventions

TypeNameDescription
DRUGatomoxetine

Timeline

Start date
2006-05-01
Primary completion
2007-03-01
Completion
2007-03-01
First posted
2006-05-19
Last updated
2011-06-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00327834. Inclusion in this directory is not an endorsement.